Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
Deals
Features
News
Region
Sectors
Size

Page 2

ImmuneID nets $50m in series A
Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.
Daily deal net: June 24, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Strand Therapeutics attaches $52m
MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.
NeuVasQ taps Theodorus for series A round
Theodorus has contributed to a $23.8m series A round for NeuVasQ, the neurological disease drug developer spun out of Université libre de Bruxelles.
Renovo Concepts concludes series A round
Wake Forest University spinout Renovo closed the round at $6.4m and will put the funding into further development of its brain injury treatment system.
Daily deal net: June 18, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Investors sign up to Nuevocor’s series A
With co-founders from Stanford University and National University of Singapore, Nuevocor aims to develop gene therapies for.
Mnemo Therapeutics redeems $91m
Alexandria Venture Investments was among the participants in a series A for the cellular cancer therapeutics developer based on work at Institut Curie and Memorial Sloan Kettering.
Daily deal net: June 17, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Veralox verifies $16.6m series A
Maryland Momentum Fund and VTC Innovation Fund have both contributed to a series A round for Veralox Therapeutics, which is focusing on diseases with unmet needs.

test reg

Login